In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $14.00. The company’s shares opened today at $1.32.
According to TipRanks, Butler is an analyst with an average return of -6.4% and a 39.36% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Cormedix, and Halozyme.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Precigen with a $10.00 average price target.
See the top stocks recommended by analysts >>
PGEN market cap is currently $296.4M and has a P/E ratio of -3.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
- Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
- PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Precigen receives FDA Breakthrough Therapy Designation for PRGN-2012
